SEC Company Response from Exousia Pro, Inc. (MAJI) (CIK 0001492448) (MAJI) — Mar 26, 2026
Exousia Pro, Inc. (MAJI) (CIK 0001492448)
Date: March 26, 2026 · CIK: 0001492448 · Accession: 0001079973-26-000363
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12629
Letter
Office of Technology Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Exousia Pro, Inc. Post-Qualification Amendment No. 4 to Offering Statement on Form 1-A Filed March 20, 2026 File No. 024-12629
Dear Ms. Graham:
This is in response to the oral comment of the Staff received March 26, 2026, relating to the captioned Post-Qualification Amendment No. 4 to the Offering Statement on Form 1-A of Nextel Medical Corp. (formerly Exousia Pro, Inc.) (the "Company").
Please be advised, that, in response to the Staff's oral comment, the filed amendment presents the new corporate name of the Company as "Nextel Medical Corp." throughout the document. Other appropriate revisions resulting from the name change have also been made.
Finally, a copy of the file-stamped Articles of Amendment reflecting the name change is included as a new exhibit.
_________________________________
Please be advised that, with respect to the selling shareholder disclosure, such disclosure has been updated to reflect the most recent disclosure standards, as discussed by the Staff and the undersigned.
Please be further advised that, in light of recent discussions between the Staff and the undersigned, the Company confirms that it understands each of the provisions of Rule 253(b), including the notes to such paragraph.
_________________________________
We believe that this filing is now in order for qualification.
Please feel free to contact the undersigned at (940) 367-6154, should you have any questions regarding this letter or the Amendment.
Thank you for your attention in this matter.
Sincerely,
NEWLAN LAW FIRM, PLLC
Show Raw Text
CORRESP 1 filename1.htm Correspondence NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road, Suite 107-762 Flower Mound, Texas 75022 March 26, 2026 Marion Graham Office of Technology Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Exousia Pro, Inc. Post-Qualification Amendment No. 4 to Offering Statement on Form 1-A Filed March 20, 2026 File No. 024-12629 Dear Ms. Graham: This is in response to the oral comment of the Staff received March 26, 2026, relating to the captioned Post-Qualification Amendment No. 4 to the Offering Statement on Form 1-A of Nextel Medical Corp. (formerly Exousia Pro, Inc.) (the "Company"). Please be advised, that, in response to the Staff's oral comment, the filed amendment presents the new corporate name of the Company as "Nextel Medical Corp." throughout the document. Other appropriate revisions resulting from the name change have also been made. Finally, a copy of the file-stamped Articles of Amendment reflecting the name change is included as a new exhibit. _________________________________ Please be advised that, with respect to the selling shareholder disclosure, such disclosure has been updated to reflect the most recent disclosure standards, as discussed by the Staff and the undersigned. Please be further advised that, in light of recent discussions between the Staff and the undersigned, the Company confirms that it understands each of the provisions of Rule 253(b), including the notes to such paragraph. _________________________________ We believe that this filing is now in order for qualification. Please feel free to contact the undersigned at (940) 367-6154, should you have any questions regarding this letter or the Amendment. Thank you for your attention in this matter. Sincerely, NEWLAN LAW FIRM, PLLC By: /s/ Eric Newlan Eric Newlan Managing Member cc: Nextel Medical Corp.